



# Prior Authorization Request Form for Antihyperuricemics

**FAX this completed form to (844) 205-3386**

**OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720**

**OR Prior authorization may be completed at <https://www.covermymeds.com/main/prior-authorization-forms/>**

I. PROVIDER INFORMATION		II. MEMBER INFORMATION	
Prescriber Name:		Member Name:	
Prescriber Specialty:		Identification #:	
NPI:		Group #:	
Office Contact Name:		Date of Birth:	
Fax #:		Medication Allergies:	
Phone #:			
III. DRUG INFORMATION (One drug request per form)			
Drug name and strength:	Dosage Interval (sig):	Qty. per Day:	
IV. REQUIRED DOCUMENTATION (Detailed medical record documentation demonstrating evidence for each item must be submitted with prior authorization request)			
Specify diagnosis & diagnosis code relevant to this request:		Dx/Dx Code: _____	
<b>Requests for non-preferred Xanthine Oxidase Inhibitor:</b> Does the member have a history of trial and failure of or contraindication or intolerance to the preferred Xanthine Oxidase Inhibitor? Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred medications in this class.		<input type="checkbox"/> Yes	Medications Taken (start and end date and dose): _____
		<input type="checkbox"/> No	_____
<b>Requests for non-preferred single-ingredient Colchicine:</b> Does the member have a history of trial and failure of or contraindication or intolerance to the preferred single-ingredient Colchicine? Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred medications in this class.		<input type="checkbox"/> Yes	Medications Taken (start and end date and dose): _____
		<input type="checkbox"/> No	_____
<b>Requests for non-preferred Antihyperuricemic:</b> Does the member have a history of trial and failure of or contraindication or intolerance to the preferred single-ingredient Antihyperuricemic? Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred medications in this class.		<input type="checkbox"/> Yes	Medications Taken (start and end date and dose): _____
		<input type="checkbox"/> No	_____
Does the member have a history of contraindication to the prescribed medication?		<input type="checkbox"/> Yes	
		<input type="checkbox"/> No	
<input type="checkbox"/> If requesting for daily quantity exceeding daily limit (Refer to <a href="https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx">https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx</a> ), please provide supporting information: _____			
SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.			
<b>KRYSTEXXA:</b>			
<input type="checkbox"/> If not prescribed by one of the following specialist rheumatologist or endocrinologist, please indicate a specialist consulted: _____			
<input type="checkbox"/> Recent uric acid level above goal based on American College of Rheumatology guidelines: _____ (submit labs)			
<input type="checkbox"/> One of the following:			
<input type="checkbox"/> Continues to have frequent gout flares ( $\geq 2$ flares/year)			
<input type="checkbox"/> Has non-resolving subcutaneous tophi			
<input type="checkbox"/> Krystexxa will not be used concomitantly with oral urate-lowering agents			

- ☐ Member was counseled regarding the following:
  - ☐ Appropriate dietary and lifestyle modifications
  - ☐ Discontinuation of other medications know to precipitate gout attacks

**KRYSTEXXA RENEWAL REQUEST:**

- ☐ Documentation of improvement in disease severity since initiating Krystexxa, as evidenced by:\_\_\_\_\_
- ☐ If not prescribed by one of the following specialist rheumatologist or endocrinologist, please indicate a specialist consulted:\_\_\_\_\_
- ☐ Does not have a history of a contraindication to Krystexxa
- ☐ Krystexxa will not be used concomitantly with oral urate-lowering agents

**IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :**

Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:
--	---------------------	-------

Pharmacy Department will respond via fax or phone within 24 hours.  
 Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)